Recurrent and chronic major depressive disorder (MDD) accounts for a substantial part of the disease burden because this course is most prevalent and typically requires long-term treatment. We associated blood DNA methylation profiles from 581 MDD patients at baseline with MDD status 6 years later. A resampling approach showed a highly significant association between methylation profiles in blood at baseline and future disease status (P = 2.0 × 10−16). Top MWAS results were enriched specific pathways, overlapped with genes found in GWAS of MDD disease status, autoimmune disease and inflammation, and co-localized with eQTLS and (genic enhancers of) of transcription sites in brain and blood. Many of these findings remained significant after correction for multiple testing. The major themes emerging were cellular responses to stress and signaling mechanisms linked to immune cell migration and inflammation. This suggests that an immune signature of treatment-resistant depression is already present at baseline. We also created a methylation risk score (MRS) to predict MDD status 6 years later. The AUC of our MRS was 0.724 and higher than risk scores created using a set of five putative MDD biomarkers, genome-wide SNP data, and 27 clinical, demographic and lifestyle variables. Although further studies are needed to examine the generalizability to different patient populations, these results suggest that methylation profiles in blood may present a promising avenue to support clinical decision making by providing empirical information about the likelihood MDD is chronic or will recur in the future.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017.
Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2009;122:184–91.
Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J psychiatry. 1999;156:1000–6.
Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science. 2010;330:612–6.
Vialou V, Feng J, Robison AJ, Nestler EJ. Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharm Toxicol. 2012;53:59–87.
Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmuhl Y, Fischer D, et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci. 2009;12:1559–66.
Volkow ND, Koob G, Baler R. Biomarkers in substance use disorders. ACS Chem Neurosci. 2015;6:522–5.
Chan RF, Shabalin AA, Xie LY, Adkins DE, Zhao M, Turecki G, et al. Enrichment methods provide a feasible approach to comprehensive and adequately powered investigations of the brain methylome. Nucl Acids Res. 2017;45:e97.
Aberg KA, Chan RF, Shabalin AA, Zhao M, Turecki G, Heine Staunstrup N, et al. A MBD-seq protocol for large-scale methylome-wide studies with (very) low amounts of DNA. Epigenetics. 2017;12:743–50.
Penninx B, Beekman A, Smit J. The Netherlands study of depression and anxiety (NESDA): rationales, objectives and methods. Int J Methods Psychiatr Res. 2008;17:121–40.
Moreland B, Oman K, Curfman J, Yan P, Bundschuh R. Methyl-CpG/MBD2 interaction requires minimum separation and exhibits minimal sequence specificity. Biophys J. 2016;111:2551–61.
Nair SS, Coolen MW, Stirzaker C, Song JZ, Statham AL, Strbenac D, et al. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics. 2011;6:34–44.
Aberg KA, McClay JL, Nerella S, Xie LY, Clark SL, Hudson AD, et al. MBD-seq as a cost-effective approach for methylome-wide association studies: demonstration in 1500 case-control samples. Epigenomics. 2012;4:605–21.
Aberg KA, Xie LY, Nerella S, Copeland WE, Costello EJ, van den Oord EJ. High quality methylome-wide investigations through next-generation sequencing of DNA from a single archived dry blood spot. Epigenetics. 2013;8:542–7.
Aberg KA, Xie L, Chan RF, Zhao M, Pandey AK, Kumar G, et al. Evaluation of methyl-binding domain based enrichment approaches revisited. PLoS ONE. 2015;10:e0132205.
Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005;37:853–62.
Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, Gu H, et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol. 2010;28:1106–14.
Lentini A, Lagerwall C, Vikingsson S, Mjoseng HK, Douvlataniotis K, Vogt H, et al. A reassessment of DNA-immunoprecipitation-based genomic profiling. Nat Methods. 2018;15:499–504.
McClay JL, Shabalin AA, Dozmorov MG, Adkins DE, Kumar G, Nerella S, et al. High density methylation QTL analysis in human blood via next-generation sequencing of the methylated genomic DNA fraction. Genome Biol. 2015;16:291.
Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 2014;71:255–64.
Shabalin AA, Hattab MW, Clark SL, Chan RF, Kumar G, Aberg KA, et al. RaMWAS: fast methylome-wide association study pipeline for enrichment platforms. Bioinformatics. 2018;34:2283–5.
Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinforma. 2012;13:86.
Hattab MW, Shabalin AA, Clark SL, Zhao M, Kumar G, Chan RF, et al. Correcting for cell-type effects in DNA methylation studies: reference-based method outperforms latent variable approaches in empirical studies. Genome Biol. 2017;18:24.
Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The reactome pathway knowledgebase. Nucl Acids Res. 2016;44:D481–7.
Cabrera CP, Navarro P, Huffman JE, Wright AF, Hayward C, Campbell H, et al. Uncovering networks from genome-wide association studies via circular genomic permutation. G3 (Bethesda). 2012;2:1067–75.
Tibshirani R, Bien J, Friedman J, Hastie T, Simon N, Taylor J, et al. Strong rules for discarding predictors in lasso-type problems. J R Stat Soc Ser B Stat Methodol. 2012;74:245–66.
Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39:1–13.
Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.
Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc B. 2005;67:301–20.
Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference, and prediction. New York: Springer Verlag; 2001.
Gerits N, Van Belle W, Moens U. Transgenic mice expressing constitutive active MAPKAPK5 display gender-dependent differences in exploration and activity. Behav Brain Funct. 2007;3:58.
Chen X, Long F, Cai B, Chen X, Chen G. A novel relationship for schizophrenia, bipolar and major depressive disorder part 3: evidence from chromosome 3 high density association screen. J Comp Neurol. 2018;526:59–79.
Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67:133–8.
Ju XD, Guo Y, Wang NN, Huang Y, Lai MM, Zhai YH, et al. Both myosin-10 isoforms are required for radial neuronal migration in the developing cerebral cortex. Cereb Cortex. 2014;24:1259–68.
Tonazzini I, Meucci S, Van Woerden GM, Elgersma Y, Cecchini M. Impaired neurite contact guidance in ubiquitin ligase E3a (Ube3a)-deficient hippocampal neurons on nanostructured substrates. Adv Health Mater. 2016;5:850–62.
Miyata S, Kurachi M, Okano Y, Sakurai N, Kobayashi A, Harada K, et al. Blood transcriptomic markers in patients with late-onset major depressive disorder. PLoS ONE. 2016;11:e0150262.
Vincent DB, Jean-Loup G, Renaud L, Etienne L. Fast unfolding of communities in large networks. J Stat Mech: Theory Exp. 2008;2008:P10008.
Csardi G, Nepusz T. The igraph software package for complex network research. Int J Complex Syst. 2006;1695:1–9.
Cancino J, Luini A. Signaling circuits on the Golgi complex. Traffic. 2013;14:121–34.
Hansen MD, Johnsen IB, Stiberg KA, Sherstova T, Wakita T, Richard GM, et al. Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M. Proc Natl Acad Sci USA. 2017;114:E3462–471.
Machamer CE. The golgi complex in stress and death. Front Neurosci. 2015;9:421.
Alvarez-Miranda EA, Sinnl M, Farhan H. Alteration of golgi structure by stress: a link to neurodegeneration? Front Neurosci. 2015;9:435.
Jawdekar GW, Henry RW. Transcriptional regulation of human small nuclear RNA genes. Biochimica et Biophysica Acta. 2008;1779:295–305.
Andersen PR, Tirian L, Vunjak M, Brennecke J. A heterochromatin-dependent transcription machinery drives piRNA expression. Nature. 2017;549:54–9.
Karijolich J, Yu Y-T. Spliceosomal snRNA modifications and their function. RNA Biol. 2010;7:192–204.
Aravin AA, Sachidanandam R, Bourc’his D, Schaefer C, Pezic D, Toth KF, et al. A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice. Mol Cell. 2008;31:785–99.
Lin R, Turecki, G. Noncoding RNAs in depression. In: Delgado-Morales R, editor. Neuroepigenomics in aging and disease. Cham: Springer International Publishing; 2017, p. 197–210.
Yang W, Wang Q, Kanes SJ, Murray JM, Nishikura K. Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy. Mol Brain Res. 2004;124:70–8.
Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, et al. Social stress induces neurovascular pathology promoting depression. Nat Neurosci. 2017;20:1752–60.
Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6:1182.
Barreiro O, De La Fuente H, Mittelbrunn M, Sánchez-Madrid F. Functional insights on the polarized redistribution of leukocyte integrins and their ligands during leukocyte migration and immune interactions. Immunological Rev. 2007;218:147–64.
Smith GC, Seaman SR, Wood AM, Royston P, White IR. Correcting for optimistic prediction in small data sets. Am J Epidemiol. 2014;180:318–24.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.
Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.
MacArthur J, Bowler E, Cerezo M, Gil L, Hall P, Hastings E, et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucl Acids Res. 2017;45:D896–901.
Gamazon ER, Segre AV, van de Bunt M, Wen X, Xi HS, Hormozdiari F, et al. Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nat Genet. 2018;50:956–67.
Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317.
Coppo P, Clauvel JP, Bengoufa D, Oksenhendler E, Lacroix C, Lassoued K. Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology. 2002;41:1040–6.
Kattah NH, Kattah MG, Utz PJ. The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunological Rev. 2010;233:126–45.
Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. 2016;17:497.
Crawford B, Craig Z, Mansell G, White I, Smith A, Spaull S, et al. DNA methylation and inflammation marker profiles associated with a history of depression. Hum Mol Genet. 2018;27:2840–50.
Benros ME, Waltoft BL, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. 2013;70:812–20.
Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2016;23:335–43.
van Loo HM, Aggen SH, Gardner CO, Kendler KS. Multiple risk factors predict recurrence of major depressive disorder in women. J Affect Disord. 2015;180:52–61.
Wardenaar KJ, van Loo HM, Cai T, Fava M, Gruber MJ, Li J, et al. The effects of co-morbidity in defining major depression subtypes associated with long-term course and severity. Psychol Med. 2014;44:3289–302.
van Loo HM, Cai T, Gruber MJ, Li J, de Jonge P, Petukhova M, et al. Major depressive disorder subtypes to predict long-term course. Depress Anxiety. 2014;31:765–77.
Nelson JC, Zhang Q, Deberdt W, Marangell LB, Karamustafalioglu O, Lipkovich IA. Predictors of remission with placebo using an integrated study database from patients with major depressive disorder. Curr Med Res Opin. 2012;28:325–34.
Riedel M, Moller HJ, Obermeier M, Adli M, Bauer M, Kronmuller K, et al. Clinical predictors of response and remission in inpatients with depressive syndromes. J Affect Disord. 2011;133:137–49.
Langie SAS, Moisse M, Declerck K, Koppen G, Godderis L, Vanden Berghe W, et al. Salivary DNA methylation profiling: aspects to consider for biomarker identification. Basic Clin Pharm Toxicol. 2017;121(Suppl 3):93–101.
Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302:2345–52.
The NESDA study is supported by the Geestkracht program of the Netherlands Organization for Health Research and Development (Zon-Mw, grant number 10-000-1002) and the participating institutions (VU University Medical Center, Leiden University Medical Center, University Medical Center Groningen. The current methylation project was supported by grant R01MH099110 from the National Institute of Mental Health. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Conflict of interest
BWJHP has obtained research funding—not related to current study—from Jansen Research and Boehringer Ingelheim. The other authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Clark, S.L., Hattab, M.W., Chan, R.F. et al. A methylation study of long-term depression risk. Mol Psychiatry 25, 1334–1343 (2020). https://doi.org/10.1038/s41380-019-0516-z
Molecular Psychiatry, August 2020: new impact factor, and highlights of recent advances in psychiatry, including an overview of the brain’s response to stress during infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Molecular Psychiatry (2020)
Single-cell mass cytometry of microglia in major depressive disorder reveals a non-inflammatory phenotype with increased homeostatic marker expression
Translational Psychiatry (2020)
Advances in depression research: second special issue, 2020, with highlights on biological mechanisms, clinical features, co-morbidity, genetics, imaging, and treatment
Molecular Psychiatry (2020)
Unraveling Mechanisms of Patient-Specific NRXN1 Mutations in Neuropsychiatric Diseases Using Human Induced Pluripotent Stem Cells
Stem Cells and Development (2020)
Advances in depression research: special issue, 2020, with three research articles by Paul Greengard
Molecular Psychiatry (2020)